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ed up at biannual and yearly intervals and data included invasive and
noninvasive investigation, and device interrogation. The estimate of
the potential survival beneﬁt of ICD was limited to appropriate ICD
shock therapies for episode of VF/VFL, since not any arrhythmic events
necessarily correspond to the true arrhythmic risk of death. We studied
our patients over a mean follow-up of 6.0 ± 4.4 years.
Antiarrhythmic drugs were used in 26 patients (93%), and in 13 pa-
tients (50%) this therapy was associated with ICD implantation [Sotalol
in 11 patients (42%) such as amiodarone; β-blockers in 4 patient (15%)].
During the follow-up 8 patients (61%), that initially received only
antiarrhythmic drugs, had an ICD implantation cause of the lack ofArrhythmogenic Right Ventrticular Dysplasia/Cardiomyopathy
(ARVD/C) is an inherited cardiomyopathy characterized by right ven-
tricularmyocyte loss with ﬁbrofatty replacement, a high risk of ventric-
ular arrhythmias (VA) and sudden cardiac death (SCD) [1]. Prevention
of SCD represents the most important management strategy and the
achievement of this target can be reached by different therapeutic
strategies including implantable cardioverter-deﬁbrillator (ICD)
implantation, pharmacologic therapy, catheter ablation of ventricular
tachycardia (VT) and cardiac transplantation [2,3]. The aim of this
study is to examine the outcome of the different therapies adopted in
a group of affected patients, focusing on the role and predictors of ICD
therapy.
We conduced a multicenter study evaluating 28 patients (18 male;
age 42 ± 14 years) with deﬁnite ARVD/C. Diagnosis of ARVD/C was
based upon the 2010 revised Task Force Criteria [4] and only patients
with deﬁnite diagnosis entered the study to enhance diagnostic speci-
ﬁcity. Management therapy was established according to the clinicaln Emodinamica, Hospital "P.
mo, Italy. Tel.: +39091343917.
di).
td. All rights reserved.features and risk stratiﬁcation of each patient. All patients were follow-
arrhythmic control. Radiofrequency catheter ablation was performed
in 6 patients (21%) and in no cases its efﬁcacy was observed because
of the recurrence of VT that required ICD implantation in whole cases.
Cardiac transplantation was performed as a ﬁnal therapeutic option
due to refractory congestive heart failure in 3 patients (10%).
At the time of the diagnosis 15 patients (54%) received an ICD
implantation based to the estimated risk of SCD, according with the
last guidelines [5] for management of patients with VA. During the
follow-up 8 patients (61%) received an ICD because of the relapse of
arrhythmic events although they were using antiarrhythmic drugs or
underwent catheter ablation. Twenty patients (86%) had received
appropriate ICD therapy. An appropriate ICD shock intervention for ven-
tricularﬁbrillation (VF)/ventricularﬂutter (VFL)was seen in 12 patients
(52%). Compared with the 100% actual survival rate, VF/VFL-free
survival rate was 96%, 94% and 51% respectively at 1, 5 and 10 years of
follow-up (logrank p b 0.0001) (Fig. 1). The estimated mortality reduc-
tion at 1, 5, 10 years of follow-up was 4%, 6% and 49% and the average
rate of ICD interventions for VF/VFL was 5%.
Univariate predictors of ICD shock therapy were a Holter premature
ventricular complex (PVC) count N500/24 h (hazard ratio [HR]: 9.44;
95% conﬁdence interval [CI]: 1.17 to 15.95; p= 0.03) and age presenta-
tion N44 years (HR: 3.71; 95% CI: 1.04 to 13.19; p = 0.04) (Table 1).
Moreover, both of them remained as signiﬁcant predictors onmultivar-
iable analysis. The positive predictive value (PPV) and the negative
Fig. 1. Kaplan–Meier analysis of survival free of VF/VFL compared with actual patient
survival. Divergence between lines reﬂects the estimated survival beneﬁt of ICD therapy.
Table 1
Predictors of appropriate ICD shock intervention.
Variable Univariable analysis Multivariable analysis
HR 95%CI p value HR 95%CI p value
PVCs N 500/24 h on Holter
monitoring
9.44 1.17–15.95 0.03 9.28 1.06–20.55 0.04
Age presentation N 44 years 3.71 1.04–13.19 0.04 6.07 1.02–2.5 0.04
NSVT 2.82 0.78–10.10 0.11 0.37 0.02–4.7 0.45
Syncope 0.64 0.19–2.11 0.47
T wave inversion (V1–V3) 0.20 0.04–0.91 0.38
Male gender 0.46 0.11–1.96 0.30
Inducibility at EPS 1.80 0.34–9.29 0.48
Epsilon wave 0.25 0.03–2.07 0.20
Prolonged QRS duration 0.76 0.2–2.90 0.69
Biventricular involvement 1.18 0.3–4.56 0.80
Family history of sudden death 0.65 0.19–2.23 0.50
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respectively, sensitivity and speciﬁcitywere 80% and 87.5% respectively.
The cumulative survival rate free of ICD therapy at 10 years was higher
(80%) in patients with low count of PVCs (≤500/24 h) compared with
patients with a high count of PVCs (24.5%) (logrank p b 0.01). Also,
the cumulative survival rate free of ICD therapy at 10 years was 71% in
patients with age presentation ≤44 years compared with 37% in pa-
tients with age presentation N44 years (logrank p = 0.02). We ﬁnally
analyzed the relationship between the number of risk factors and ICD
shock therapy. We found that patients with one or two risk factors
had a signiﬁcantly increased risk of ICD therapy. The 5-year survival
rates free of appropriate ICD shock therapy for patients with 0 or 2
risk factors were 100% and 75%, respectively (logrank p = 0.002).
The prevention of life-threatening arrhythmias is the most important
management strategy in ARVD/C patients and risk stratiﬁcation
represents an essential step to achieve this target [6]. However in many
cases the choice can be a difﬁcult cause of the rarity and the clinical
heterogeneity of the disease [7]. According to literature [8–10], even our
study conﬁrms the predominant role of ICD implantation as the ﬁrst-
line therapy and suggests the secondary employment of other therapeutic
options, when used as unique treatment, only in patients with hemody-
namically stable arrhythmias, or asymptomatic mutation carriers or pa-
tient with borderline or possible diagnosis of ARVD/C [6]. We moreover
identiﬁed two clinical variables as signiﬁcant predictors of appropriate
ICD shock therapy and the combination of these risk factors portends an
incremental risk. We thought that a very frequent Holter monitoring
PVC count represents a marker of electrical instability leading to ventric-
ular arrhythmias. Moreover patients whose presentation starts over thethird decade, conceal an important anatomical damage, including myo-
cardial and conduction tissue, underlying their high risk of VA. This ﬁnd-
ing can be usefully employed to risk-stratify patients who need ICD
implantation.
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